Pro-Dex, Inc.
Pro-Dex, Inc. PDEX Peers
See (PDEX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PDEX | $43.12 | -0.51% | 140.62M | 15.62 | $2.76 | N/A |
| ISRG | $560.28 | -1.00% | 200.81B | 82.15 | $6.82 | N/A |
| BDX | $172.19 | +0.68% | 49.35B | 33.37 | $5.16 | +2.32% |
| BDXA | $59.24 | -2.24% | 47.95B | 21.44 | $2.76 | +2.32% |
| ALC | $87.62 | +0.44% | 43.34B | 38.94 | $2.25 | +0.38% |
| RMD | $248.46 | +0.60% | 36.43B | 27.85 | $8.92 | +0.85% |
| COO | $81.45 | +1.22% | 16.29B | 39.35 | $2.07 | N/A |
| BAX | $31.04 | +2.37% | 15.93B | -59.69 | -$0.52 | +2.98% |
| WST | $210.69 | +1.93% | 15.14B | 33.07 | $6.37 | +0.39% |
| BDXB | $48.16 | +1.39% | 13.69B | 7.60 | $6.33 | +2.32% |
Stock Comparison
PDEX vs ISRG Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, ISRG has a market cap of 200.81B. Regarding current trading prices, PDEX is priced at $43.12, while ISRG trades at $560.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas ISRG's P/E ratio is 82.15. In terms of profitability, PDEX's ROE is +0.29%, compared to ISRG's ROE of +0.16%. Regarding short-term risk, PDEX is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.
PDEX vs BDX Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, BDX has a market cap of 49.35B. Regarding current trading prices, PDEX is priced at $43.12, while BDX trades at $172.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas BDX's P/E ratio is 33.37. In terms of profitability, PDEX's ROE is +0.29%, compared to BDX's ROE of +0.06%. Regarding short-term risk, PDEX is more volatile compared to BDX. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.
PDEX vs BDXA Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, BDXA has a market cap of 47.95B. Regarding current trading prices, PDEX is priced at $43.12, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas BDXA's P/E ratio is 21.44. In terms of profitability, PDEX's ROE is +0.29%, compared to BDXA's ROE of +0.06%. Regarding short-term risk, PDEX is less volatile compared to BDXA. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs ALC Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, ALC has a market cap of 43.34B. Regarding current trading prices, PDEX is priced at $43.12, while ALC trades at $87.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas ALC's P/E ratio is 38.94. In terms of profitability, PDEX's ROE is +0.29%, compared to ALC's ROE of +0.06%. Regarding short-term risk, PDEX is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.
PDEX vs RMD Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, RMD has a market cap of 36.43B. Regarding current trading prices, PDEX is priced at $43.12, while RMD trades at $248.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas RMD's P/E ratio is 27.85. In terms of profitability, PDEX's ROE is +0.29%, compared to RMD's ROE of +0.25%. Regarding short-term risk, PDEX is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.
PDEX vs COO Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, COO has a market cap of 16.29B. Regarding current trading prices, PDEX is priced at $43.12, while COO trades at $81.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas COO's P/E ratio is 39.35. In terms of profitability, PDEX's ROE is +0.29%, compared to COO's ROE of +0.05%. Regarding short-term risk, PDEX is more volatile compared to COO. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.
PDEX vs BAX Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, BAX has a market cap of 15.93B. Regarding current trading prices, PDEX is priced at $43.12, while BAX trades at $31.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas BAX's P/E ratio is -59.69. In terms of profitability, PDEX's ROE is +0.29%, compared to BAX's ROE of -0.07%. Regarding short-term risk, PDEX is more volatile compared to BAX. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.
PDEX vs WST Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, WST has a market cap of 15.14B. Regarding current trading prices, PDEX is priced at $43.12, while WST trades at $210.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas WST's P/E ratio is 33.07. In terms of profitability, PDEX's ROE is +0.29%, compared to WST's ROE of +0.17%. Regarding short-term risk, PDEX is less volatile compared to WST. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs BDXB Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, BDXB has a market cap of 13.69B. Regarding current trading prices, PDEX is priced at $43.12, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas BDXB's P/E ratio is 7.60. In terms of profitability, PDEX's ROE is +0.29%, compared to BDXB's ROE of +0.06%. Regarding short-term risk, PDEX is more volatile compared to BDXB. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.
PDEX vs HOLX Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, HOLX has a market cap of 12.42B. Regarding current trading prices, PDEX is priced at $43.12, while HOLX trades at $55.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas HOLX's P/E ratio is 23.42. In terms of profitability, PDEX's ROE is +0.29%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, PDEX is more volatile compared to HOLX. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.
PDEX vs ATR Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, ATR has a market cap of 10.24B. Regarding current trading prices, PDEX is priced at $43.12, while ATR trades at $155.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas ATR's P/E ratio is 28.34. In terms of profitability, PDEX's ROE is +0.29%, compared to ATR's ROE of +0.15%. Regarding short-term risk, PDEX is more volatile compared to ATR. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.
PDEX vs MASI Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, MASI has a market cap of 8.37B. Regarding current trading prices, PDEX is priced at $43.12, while MASI trades at $154.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas MASI's P/E ratio is -28.28. In terms of profitability, PDEX's ROE is +0.29%, compared to MASI's ROE of -0.41%. Regarding short-term risk, PDEX is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.
PDEX vs RGEN Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, RGEN has a market cap of 6.93B. Regarding current trading prices, PDEX is priced at $43.12, while RGEN trades at $123.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas RGEN's P/E ratio is -293.48. In terms of profitability, PDEX's ROE is +0.29%, compared to RGEN's ROE of -0.01%. Regarding short-term risk, PDEX is less volatile compared to RGEN. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs STVN Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, STVN has a market cap of 6.36B. Regarding current trading prices, PDEX is priced at $43.12, while STVN trades at $23.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas STVN's P/E ratio is 45.69. In terms of profitability, PDEX's ROE is +0.29%, compared to STVN's ROE of +0.09%. Regarding short-term risk, PDEX is less volatile compared to STVN. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs MMSI Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, MMSI has a market cap of 5.77B. Regarding current trading prices, PDEX is priced at $43.12, while MMSI trades at $97.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas MMSI's P/E ratio is 47.83. In terms of profitability, PDEX's ROE is +0.29%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, PDEX is more volatile compared to MMSI. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.
PDEX vs TFX Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, TFX has a market cap of 5.60B. Regarding current trading prices, PDEX is priced at $43.12, while TFX trades at $126.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas TFX's P/E ratio is 39.20. In terms of profitability, PDEX's ROE is +0.29%, compared to TFX's ROE of +0.03%. Regarding short-term risk, PDEX is more volatile compared to TFX. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.
PDEX vs BLCO Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, BLCO has a market cap of 4.17B. Regarding current trading prices, PDEX is priced at $43.12, while BLCO trades at $11.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas BLCO's P/E ratio is -11.57. In terms of profitability, PDEX's ROE is +0.29%, compared to BLCO's ROE of -0.08%. Regarding short-term risk, PDEX is less volatile compared to BLCO. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs HAE Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, HAE has a market cap of 3.49B. Regarding current trading prices, PDEX is priced at $43.12, while HAE trades at $69.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas HAE's P/E ratio is 20.97. In terms of profitability, PDEX's ROE is +0.29%, compared to HAE's ROE of +0.18%. Regarding short-term risk, PDEX is more volatile compared to HAE. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.
PDEX vs ICUI Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, ICUI has a market cap of 3.46B. Regarding current trading prices, PDEX is priced at $43.12, while ICUI trades at $140.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas ICUI's P/E ratio is -36.69. In terms of profitability, PDEX's ROE is +0.29%, compared to ICUI's ROE of -0.05%. Regarding short-term risk, PDEX is less volatile compared to ICUI. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs XRAY Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, XRAY has a market cap of 3.29B. Regarding current trading prices, PDEX is priced at $43.12, while XRAY trades at $16.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas XRAY's P/E ratio is -3.69. In terms of profitability, PDEX's ROE is +0.29%, compared to XRAY's ROE of -0.38%. Regarding short-term risk, PDEX is more volatile compared to XRAY. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.
PDEX vs QDEL Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, QDEL has a market cap of 2.23B. Regarding current trading prices, PDEX is priced at $43.12, while QDEL trades at $33.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas QDEL's P/E ratio is -6.32. In terms of profitability, PDEX's ROE is +0.29%, compared to QDEL's ROE of -0.11%. Regarding short-term risk, PDEX is less volatile compared to QDEL. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs WRBY Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, WRBY has a market cap of 2.13B. Regarding current trading prices, PDEX is priced at $43.12, while WRBY trades at $17.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas WRBY's P/E ratio is -146.42. In terms of profitability, PDEX's ROE is +0.29%, compared to WRBY's ROE of -0.04%. Regarding short-term risk, PDEX is more volatile compared to WRBY. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.
PDEX vs NVCR Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, NVCR has a market cap of 1.96B. Regarding current trading prices, PDEX is priced at $43.12, while NVCR trades at $17.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas NVCR's P/E ratio is -11.65. In terms of profitability, PDEX's ROE is +0.29%, compared to NVCR's ROE of -0.45%. Regarding short-term risk, PDEX is less volatile compared to NVCR. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs LMAT Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, LMAT has a market cap of 1.88B. Regarding current trading prices, PDEX is priced at $43.12, while LMAT trades at $83.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas LMAT's P/E ratio is 42.28. In terms of profitability, PDEX's ROE is +0.29%, compared to LMAT's ROE of +0.14%. Regarding short-term risk, PDEX is more volatile compared to LMAT. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.
PDEX vs ATRC Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, ATRC has a market cap of 1.60B. Regarding current trading prices, PDEX is priced at $43.12, while ATRC trades at $32.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas ATRC's P/E ratio is -39.88. In terms of profitability, PDEX's ROE is +0.29%, compared to ATRC's ROE of -0.08%. Regarding short-term risk, PDEX is more volatile compared to ATRC. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.
PDEX vs AZTA Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, AZTA has a market cap of 1.22B. Regarding current trading prices, PDEX is priced at $43.12, while AZTA trades at $26.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas AZTA's P/E ratio is -8.17. In terms of profitability, PDEX's ROE is +0.29%, compared to AZTA's ROE of -0.04%. Regarding short-term risk, PDEX is more volatile compared to AZTA. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.
PDEX vs KMTS Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, KMTS has a market cap of 1.22B. Regarding current trading prices, PDEX is priced at $43.12, while KMTS trades at $23.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas KMTS's P/E ratio is -12.37. In terms of profitability, PDEX's ROE is +0.29%, compared to KMTS's ROE of N/A. Regarding short-term risk, PDEX is less volatile compared to KMTS. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs PLSE Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, PLSE has a market cap of 1.11B. Regarding current trading prices, PDEX is priced at $43.12, while PLSE trades at $16.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas PLSE's P/E ratio is -16.66. In terms of profitability, PDEX's ROE is +0.29%, compared to PLSE's ROE of -0.71%. Regarding short-term risk, PDEX is less volatile compared to PLSE. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs BLFS Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, BLFS has a market cap of 1.05B. Regarding current trading prices, PDEX is priced at $43.12, while BLFS trades at $21.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas BLFS's P/E ratio is -115.74. In terms of profitability, PDEX's ROE is +0.29%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, PDEX is less volatile compared to BLFS. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs STAA Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, STAA has a market cap of 905.83M. Regarding current trading prices, PDEX is priced at $43.12, while STAA trades at $18.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas STAA's P/E ratio is -12.70. In terms of profitability, PDEX's ROE is +0.29%, compared to STAA's ROE of -0.18%. Regarding short-term risk, PDEX is less volatile compared to STAA. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs ATRI Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, ATRI has a market cap of 809.44M. Regarding current trading prices, PDEX is priced at $43.12, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas ATRI's P/E ratio is 64.50. In terms of profitability, PDEX's ROE is +0.29%, compared to ATRI's ROE of +0.05%. Regarding short-term risk, PDEX is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.
PDEX vs ANGO Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, ANGO has a market cap of 372.37M. Regarding current trading prices, PDEX is priced at $43.12, while ANGO trades at $9.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas ANGO's P/E ratio is -9.08. In terms of profitability, PDEX's ROE is +0.29%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, PDEX is more volatile compared to ANGO. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.
PDEX vs NNNN Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, NNNN has a market cap of 327.43M. Regarding current trading prices, PDEX is priced at $43.12, while NNNN trades at $7.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas NNNN's P/E ratio is 149.20. In terms of profitability, PDEX's ROE is +0.29%, compared to NNNN's ROE of N/A. Regarding short-term risk, PDEX is less volatile compared to NNNN. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs SMTI Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, SMTI has a market cap of 278.19M. Regarding current trading prices, PDEX is priced at $43.12, while SMTI trades at $31.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas SMTI's P/E ratio is -27.46. In terms of profitability, PDEX's ROE is +0.29%, compared to SMTI's ROE of -0.24%. Regarding short-term risk, PDEX is less volatile compared to SMTI. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs NYXH Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, NYXH has a market cap of 214.23M. Regarding current trading prices, PDEX is priced at $43.12, while NYXH trades at $6.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas NYXH's P/E ratio is -3.10. In terms of profitability, PDEX's ROE is +0.29%, compared to NYXH's ROE of -0.56%. Regarding short-term risk, PDEX is less volatile compared to NYXH. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs OSUR Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, OSUR has a market cap of 183.63M. Regarding current trading prices, PDEX is priced at $43.12, while OSUR trades at $2.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas OSUR's P/E ratio is -5.85. In terms of profitability, PDEX's ROE is +0.29%, compared to OSUR's ROE of -0.08%. Regarding short-term risk, PDEX is less volatile compared to OSUR. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs UTMD Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, UTMD has a market cap of 180.01M. Regarding current trading prices, PDEX is priced at $43.12, while UTMD trades at $54.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas UTMD's P/E ratio is 14.47. In terms of profitability, PDEX's ROE is +0.29%, compared to UTMD's ROE of +0.11%. Regarding short-term risk, PDEX is more volatile compared to UTMD. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.
PDEX vs STXS Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, STXS has a market cap of 176.26M. Regarding current trading prices, PDEX is priced at $43.12, while STXS trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas STXS's P/E ratio is -6.83. In terms of profitability, PDEX's ROE is +0.29%, compared to STXS's ROE of -2.17%. Regarding short-term risk, PDEX is less volatile compared to STXS. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs ZTEK Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, ZTEK has a market cap of 163.68M. Regarding current trading prices, PDEX is priced at $43.12, while ZTEK trades at $1.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas ZTEK's P/E ratio is -19.61. In terms of profitability, PDEX's ROE is +0.29%, compared to ZTEK's ROE of -0.58%. Regarding short-term risk, PDEX is less volatile compared to ZTEK. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs KRMD Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, KRMD has a market cap of 141.19M. Regarding current trading prices, PDEX is priced at $43.12, while KRMD trades at $3.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas KRMD's P/E ratio is -25.50. In terms of profitability, PDEX's ROE is +0.29%, compared to KRMD's ROE of -0.30%. Regarding short-term risk, PDEX is less volatile compared to KRMD. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs ZJYL Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, ZJYL has a market cap of 129.15M. Regarding current trading prices, PDEX is priced at $43.12, while ZJYL trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas ZJYL's P/E ratio is 41.25. In terms of profitability, PDEX's ROE is +0.29%, compared to ZJYL's ROE of +0.13%. Regarding short-term risk, PDEX is less volatile compared to ZJYL. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs INFU Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, INFU has a market cap of 126.17M. Regarding current trading prices, PDEX is priced at $43.12, while INFU trades at $6.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas INFU's P/E ratio is 40.10. In terms of profitability, PDEX's ROE is +0.29%, compared to INFU's ROE of +0.08%. Regarding short-term risk, PDEX is less volatile compared to INFU. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs MBOT Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, MBOT has a market cap of 92.77M. Regarding current trading prices, PDEX is priced at $43.12, while MBOT trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas MBOT's P/E ratio is -3.66. In terms of profitability, PDEX's ROE is +0.29%, compared to MBOT's ROE of -2.34%. Regarding short-term risk, PDEX is less volatile compared to MBOT. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs MLSS Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, MLSS has a market cap of 72.11M. Regarding current trading prices, PDEX is priced at $43.12, while MLSS trades at $0.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas MLSS's P/E ratio is -15.33. In terms of profitability, PDEX's ROE is +0.29%, compared to MLSS's ROE of -0.66%. Regarding short-term risk, PDEX is more volatile compared to MLSS. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.
PDEX vs OMIC Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, OMIC has a market cap of 50.77M. Regarding current trading prices, PDEX is priced at $43.12, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas OMIC's P/E ratio is -0.58. In terms of profitability, PDEX's ROE is +0.29%, compared to OMIC's ROE of -0.58%. Regarding short-term risk, PDEX is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.
PDEX vs IGAP Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, IGAP has a market cap of 50.23M. Regarding current trading prices, PDEX is priced at $43.12, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas IGAP's P/E ratio is -10.52. In terms of profitability, PDEX's ROE is +0.29%, compared to IGAP's ROE of +4.55%. Regarding short-term risk, PDEX is more volatile compared to IGAP. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.
PDEX vs AKYA Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, AKYA has a market cap of 49.87M. Regarding current trading prices, PDEX is priced at $43.12, while AKYA trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas AKYA's P/E ratio is -0.96. In terms of profitability, PDEX's ROE is +0.29%, compared to AKYA's ROE of -5.06%. Regarding short-term risk, PDEX is less volatile compared to AKYA. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs POCI Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, POCI has a market cap of 36.57M. Regarding current trading prices, PDEX is priced at $43.12, while POCI trades at $4.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas POCI's P/E ratio is -7.34. In terms of profitability, PDEX's ROE is +0.29%, compared to POCI's ROE of -0.39%. Regarding short-term risk, PDEX is more volatile compared to POCI. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.
PDEX vs DXR Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, DXR has a market cap of 36.37M. Regarding current trading prices, PDEX is priced at $43.12, while DXR trades at $7.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas DXR's P/E ratio is -83.56. In terms of profitability, PDEX's ROE is +0.29%, compared to DXR's ROE of +0.02%. Regarding short-term risk, PDEX is more volatile compared to DXR. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.
PDEX vs FEMY Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, FEMY has a market cap of 29.15M. Regarding current trading prices, PDEX is priced at $43.12, while FEMY trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas FEMY's P/E ratio is -1.18. In terms of profitability, PDEX's ROE is +0.29%, compared to FEMY's ROE of -3.92%. Regarding short-term risk, PDEX is more volatile compared to FEMY. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.
PDEX vs SDC Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, SDC has a market cap of 29.11M. Regarding current trading prices, PDEX is priced at $43.12, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas SDC's P/E ratio is -0.03. In terms of profitability, PDEX's ROE is +0.29%, compared to SDC's ROE of -1.96%. Regarding short-term risk, PDEX is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs IVC Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, IVC has a market cap of 24.91M. Regarding current trading prices, PDEX is priced at $43.12, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas IVC's P/E ratio is -0.79. In terms of profitability, PDEX's ROE is +0.29%, compared to IVC's ROE of -0.46%. Regarding short-term risk, PDEX is less volatile compared to IVC. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs NEPH Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, NEPH has a market cap of 22.68M. Regarding current trading prices, PDEX is priced at $43.12, while NEPH trades at $2.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas NEPH's P/E ratio is 214.00. In terms of profitability, PDEX's ROE is +0.29%, compared to NEPH's ROE of +0.09%. Regarding short-term risk, PDEX is more volatile compared to NEPH. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.
PDEX vs RVP Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, RVP has a market cap of 22.45M. Regarding current trading prices, PDEX is priced at $43.12, while RVP trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas RVP's P/E ratio is -1.87. In terms of profitability, PDEX's ROE is +0.29%, compared to RVP's ROE of -0.13%. Regarding short-term risk, PDEX is less volatile compared to RVP. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs NXGLW Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, NXGLW has a market cap of 19.27M. Regarding current trading prices, PDEX is priced at $43.12, while NXGLW trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas NXGLW's P/E ratio is -0.22. In terms of profitability, PDEX's ROE is +0.29%, compared to NXGLW's ROE of -0.68%. Regarding short-term risk, PDEX is less volatile compared to NXGLW. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs NXGL Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, NXGL has a market cap of 18.52M. Regarding current trading prices, PDEX is priced at $43.12, while NXGL trades at $2.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas NXGL's P/E ratio is -4.84. In terms of profitability, PDEX's ROE is +0.29%, compared to NXGL's ROE of -0.68%. Regarding short-term risk, PDEX is less volatile compared to NXGL. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs HBIO Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, HBIO has a market cap of 15.67M. Regarding current trading prices, PDEX is priced at $43.12, while HBIO trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas HBIO's P/E ratio is -1.27. In terms of profitability, PDEX's ROE is +0.29%, compared to HBIO's ROE of -1.10%. Regarding short-term risk, PDEX is less volatile compared to HBIO. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs LUCYW Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, LUCYW has a market cap of 13.82M. Regarding current trading prices, PDEX is priced at $43.12, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas LUCYW's P/E ratio is N/A. In terms of profitability, PDEX's ROE is +0.29%, compared to LUCYW's ROE of -0.99%. Regarding short-term risk, PDEX is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs MHUA Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, MHUA has a market cap of 12.67M. Regarding current trading prices, PDEX is priced at $43.12, while MHUA trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas MHUA's P/E ratio is 1.00. In terms of profitability, PDEX's ROE is +0.29%, compared to MHUA's ROE of +0.09%. Regarding short-term risk, PDEX is less volatile compared to MHUA. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs EKSO Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, EKSO has a market cap of 11.62M. Regarding current trading prices, PDEX is priced at $43.12, while EKSO trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas EKSO's P/E ratio is -0.83. In terms of profitability, PDEX's ROE is +0.29%, compared to EKSO's ROE of -0.82%. Regarding short-term risk, PDEX is less volatile compared to EKSO. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs POAI Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, POAI has a market cap of 9.82M. Regarding current trading prices, PDEX is priced at $43.12, while POAI trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas POAI's P/E ratio is -0.55. In terms of profitability, PDEX's ROE is +0.29%, compared to POAI's ROE of -5.11%. Regarding short-term risk, PDEX is less volatile compared to POAI. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs LUCY Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, LUCY has a market cap of 8.64M. Regarding current trading prices, PDEX is priced at $43.12, while LUCY trades at $2.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas LUCY's P/E ratio is -0.26. In terms of profitability, PDEX's ROE is +0.29%, compared to LUCY's ROE of -0.99%. Regarding short-term risk, PDEX is less volatile compared to LUCY. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs WOK Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, WOK has a market cap of 8.17M. Regarding current trading prices, PDEX is priced at $43.12, while WOK trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas WOK's P/E ratio is -2.07. In terms of profitability, PDEX's ROE is +0.29%, compared to WOK's ROE of N/A. Regarding short-term risk, PDEX is less volatile compared to WOK. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs NSTG Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, NSTG has a market cap of 5.07M. Regarding current trading prices, PDEX is priced at $43.12, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas NSTG's P/E ratio is -0.03. In terms of profitability, PDEX's ROE is +0.29%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, PDEX is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs STSS Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, STSS has a market cap of 4.60M. Regarding current trading prices, PDEX is priced at $43.12, while STSS trades at $4.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas STSS's P/E ratio is N/A. In terms of profitability, PDEX's ROE is +0.29%, compared to STSS's ROE of -1.65%. Regarding short-term risk, PDEX is more volatile compared to STSS. This indicates potentially higher risk in terms of short-term price fluctuations for PDEX.
PDEX vs GCTK Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, GCTK has a market cap of 3.83M. Regarding current trading prices, PDEX is priced at $43.12, while GCTK trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas GCTK's P/E ratio is N/A. In terms of profitability, PDEX's ROE is +0.29%, compared to GCTK's ROE of +4.55%. Regarding short-term risk, PDEX is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs GMVD Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, GMVD has a market cap of 1.80M. Regarding current trading prices, PDEX is priced at $43.12, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas GMVD's P/E ratio is -0.01. In terms of profitability, PDEX's ROE is +0.29%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, PDEX is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs GMVDW Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, GMVDW has a market cap of 1.80M. Regarding current trading prices, PDEX is priced at $43.12, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas GMVDW's P/E ratio is N/A. In terms of profitability, PDEX's ROE is +0.29%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, PDEX is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.
PDEX vs AVGR Comparison
PDEX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 140.62M. In comparison, AVGR has a market cap of 1.52M. Regarding current trading prices, PDEX is priced at $43.12, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 15.62, whereas AVGR's P/E ratio is -0.05. In terms of profitability, PDEX's ROE is +0.29%, compared to AVGR's ROE of -54.25%. Regarding short-term risk, PDEX is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for PDEX.